These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9738175)

  • 1. Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group.
    Heininger U; Cherry JD; Stehr K; Schmitt-Grohé S; Uberall M; Laussucq S; Eckhardt T; Meyer M; Gornbein J
    Pediatrics; 1998 Sep; 102(3 Pt 1):546-53. PubMed ID: 9738175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
    Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
    Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K; Cherry JD
    Dev Biol Stand; 1997; 89():58-62. PubMed ID: 9333571
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine.
    Lugauer S; Heininger U; Cherry JD; Stehr K
    Eur J Pediatr; 2002 Mar; 161(3):142-6. PubMed ID: 11998910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial.
    Cherry JD; Heininger U; Stehr K; Christenson P
    Pediatrics; 1998 Oct; 102(4 Pt 1):909-12. PubMed ID: 9755264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of Lederle/Takeda acellular and Lederle whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants in Germany.
    Heininger U; Cherry JD; Christenson PD; Eckhardt T; Göering U; Jakob P; Kasper W; Schweingel D; Laussucq S; Hackell JG
    Vaccine; 1994 Jan; 12(1):81-6. PubMed ID: 8303945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A placebo-controlled trial of a pertussis-toxoid vaccine.
    Trollfors B; Taranger J; Lagergård T; Lind L; Sundh V; Zackrisson G; Lowe CU; Blackwelder W; Robbins JB
    N Engl J Med; 1995 Oct; 333(16):1045-50. PubMed ID: 7675047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups.
    Cherry JD; Mortimer EA; Hackell JG; Scott JV
    Dev Biol Stand; 1991; 73():51-8. PubMed ID: 1778334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implications of endotoxin concentrations in vaccines.
    Geier DA; Geier MR
    Ann Pharmacother; 2002 May; 36(5):776-80. PubMed ID: 11978151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial.
    Heininger U; Schmidt-Schläpfer G; Cherry JD; Stehr K
    Pediatrics; 2000 Mar; 105(3):E31. PubMed ID: 10699133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
    Olin P; Rasmussen F; Gustafsson L; Hallander HO; Heijbel H
    Lancet; 1997 Nov; 350(9091):1569-77. PubMed ID: 9393335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
    Englund JA; Anderson EL; Reed GF; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Rennels MB; Deforest A; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):580-4. PubMed ID: 7659480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.